SecBot SecBot
PRESS-RELEASE ·Filed Aug 26, 2026
RN

RNAQU

Rainier Acquisition Corp.
NEUTRAL
Impact 4/10
Horizonweeks Processed2mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight • Neutral

Monitor for the closing of the IPO and subsequent trading of units. The SPAC's search for a life sciences target will be the primary catalyst; any announcement of a definitive agreement or letter of intent will drive significant price movement. The 45-day over-allotment option could add up to $11.25M in additional proceeds if exercised.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d
RNAQU ▲ +0.10% at T+20d
NEUTRAL call +0.10% · α vs SPY +0.61% · entry $10.16 → $10.17
Next anchor: T+60d in 23d
Entry = T+0 close
Aug 26, 2026
via day close
T+1d
+0.15%
call +0.15% · α +0.37%
$10.18
settled 2mo ago
T+5d
+0.39%
call +0.39% · α +0.13%
$10.20
settled 8w ago
T+20d
+0.10%
call +0.10% · α +0.61%
$10.17
settled 5w ago
T+60d
Pending
in 23d

Price Chart

Loading chart...

Executive Summary

Rainier Acquisition Corp. (RNAQU) priced its $75M IPO of 7.5M units at $10/unit, each consisting of one Class A share and one-quarter warrant exercisable at $11.50. The SPAC will target life sciences businesses for a future business combination, with units trading on Nasdaq starting August 27, 2026.

Key Financial Metrics

Deal Value
$75.0M

Key Facts

  • IPO of 7,500,000 units at $10.00 per unit, gross proceeds of $75,000,000
  • Each unit: one Class A ordinary share + one-quarter redeemable warrant (exercise price $11.50 per share)
  • Units to trade on Nasdaq under 'RNAQU' starting August 27, 2026; shares and warrants under 'RNAQ' and 'RNAQW' after separation
  • Underwriter Chardan has 45-day option to purchase up to 1,125,000 additional units for over-allotments
  • SPAC targeting global life sciences industries (therapeutics, diagnostics, genomics, precision medicine, etc.)
  • Management: CEO Gbola Amusa, MD, CFA; CFO Guy Barudin
  • Offering expected to close August 28, 2026

Financial Impact

Gross proceeds of $75,000,000 before underwriting discounts and expenses

cashdilutionshare count

Risk Factors

  • No identified target yet; SPAC may fail to complete a business combination within the required timeframe
  • Life sciences focus carries execution risk and regulatory uncertainty for any target
  • Warrant dilution if exercised (11.5M shares if all warrants exercised at $11.50)
  • Underwriter over-allotment could increase dilution by up to 1.125M additional units

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3351735
3 reports for RNAQU
Performance horizon
Filters
Rows
Reports for RNAQU — sortable, filterable
TypeNow
Sep 2, 2026
7w ago
Press Release
NEUTRAL ★ 3/10
$10.18 $10.07▼ −1.13%▼ −0.98%$10.03 (−1.47%)
Aug 28, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$10.18 $10.18▲ +0.04%▼ −0.22%$10.03 (−1.43%)
Aug 26, 2026
8w ago
Press Release
NEUTRAL ★ 4/10
$10.16 $10.17▲ +0.10%▲ +0.61%$10.03 (−1.28%)
Showing 3 of 3

US Market Status

Market Closed — Opens Wed (11h 57m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 26, 2026